Choosing a workspace for clinical study data is usually framed as a features comparison: can it store datasets, can it show documents, can it run a query? Those are table stakes. The harder due diligence starts when a study team asks how the workspace behaves when roles overlap, when blinding matters, when an auditor reconstructs a decision, and when an assistant is allowed to touch study data. A platform that supports clinical study data analytics should answer those questions with specific controls, not general assurances. The questions are designed to be asked in a demo, not only in a security questionnaire.
Ask How Roles Are Scoped to Each Study
A role model that works for a small team can fail across a portfolio. Ask whether access is granted by study or by organization, and whether the same person can hold different roles on different studies. The useful model is one where a user sees only the studies they belong to and is assigned a role such as viewer, collaborator or owner for each one. Then test the edges: What happens when a statistician joins midway through a study? Can a data manager be a collaborator on one protocol and a viewer on another? Who can change membership, and is that change visible to the study lead?
Per-study roles also shape collaboration. If notes and issues attach to the exact form, field, row or document page, then the permission to comment should follow the same study boundary. Ask whether a reviewer can see a record they are discussing without gaining access to every study in the account. The answer should be demonstrable in the workspace, not buried in a policy document. A role model that is too coarse creates workarounds; one that is too complex creates administrative drag. The right balance is usually a small set of named roles that map to how study teams actually work. In a demo, assign a reviewer to one study, add a comment to a field, then confirm that the same reviewer cannot see a second study’s records.
Test Blinding as a Grant, Not a View Toggle
Blinding is where generic collaboration tools often become unsafe. Ask a blunt question: if a user has a role that normally allows broad access, what stops them from seeing unblinded content? The acceptable answer is that unblinded content requires its own grant, independent of the person’s ordinary role. That grant should control files, records and search results, because a hidden file is not hidden if its title or a result snippet appears in a search. Press on the details: Are page-by-page document results filtered? Are dataset rows filtered? Does the grant follow a person across data cuts, or must it be reissued when a new cut is loaded?
Study teams should also ask who can issue, review and revoke the unblinding grant. If the same administrator who manages membership can quietly grant unblinded access, the control is only procedural. Ask whether the grant event is written to the audit trail and whether the study lead can see the current list of granted users. Blinding is not a checkbox on a setup form; it is a persistent access design that must survive new files, new cuts and new team members. A workspace that treats it as a separate grant is easier to defend during review than one that relies on people remembering not to click a tab.
Interrogate the Audit Trail as an Operational Record
An audit trail is often described as a log, but study teams need to know whether it can support reconstruction. Ask whether the trail is append-only, and whether changes to membership, roles, unblinding and records all land in the same place. Then ask what happens when data is corrected: are records retired or superseded, and are file revisions retained? The distinction matters. If a record can be overwritten without a trace, the trail tells a story with missing pages. If each data cut is kept as its own version with a checksum, the team can compare cuts and explain what changed between them.
Practical questions follow: Can the study lead filter the trail by person, study, role change or unblinding event? Is the trail readable by someone who was not involved in the day-to-day work? Does it distinguish a role change from a data change? These questions are not about producing a thicker binder. They are about reducing the time spent reconstructing why a dataset looked different at a review meeting. A workspace that keeps versions in order and records access changes in an append-only log gives the team a defensible narrative without relying on memory. Ask for a demonstration that starts with a role change and ends with a revised data cut, so the team can see how the trail connects the two.
Pressure-Test the Assistant Sandbox and the Visibility of Its Work
If the workspace includes a question-answering assistant, the study team should treat it as another data user with its own permissions. Ask where the code runs, what data it can reach, and how long that access lasts. The strongest answer is specific: an isolated sandbox, read-only access to one study, and short-lived access rather than standing access to the whole account. Then ask what the team sees after a question is answered. If the assistant writes Python and runs it on the study data, the code and the results should both be visible so a statistician can check the steps. An answer without the working is a conclusion without a chain of custody.
Use a short list of verification questions in a demo:
Can the assistant reach data from a study the user cannot open?
Does it run with read-only access, and is that access limited in time?
Are the code and the output shown together for every answer?
Can a statistician reproduce the result from the visible code and the chosen data cut?
Are assistant actions and access changes captured in the same audit trail as other study activity?
What happens when the question touches unblinded content without the required grant?
These are not abstract security questions. They determine whether the assistant becomes a useful reviewer or a new source of unexplained numbers. The same discipline applies to the rest of the workspace: each study should have its own boundary, each data cut should be identifiable, and each change should be traceable. When a vendor can demonstrate those behaviors on your study, the evaluation moves from promises to evidence.